Expand IGC Menu
IGC MENU

IGC Latest Press Releases

-- April 14, 2026 --

IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout ACCESS Newswire 8:30 AM

-- April 8, 2026 --

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts ACCESS Newswire 12:45 PM

-- April 7, 2026 --

IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease ACCESS Newswire 8:00 AM

-- March 30, 2026 --

IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness ACCESS Newswire 8:00 AM

-- March 19, 2026 --

IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 ACCESS Newswire 9:05 AM

-- March 18, 2026 --

IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026 ACCESS Newswire 9:00 AM

-- February 26, 2026 --

IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research ACCESS Newswire 8:30 AM

-- February 23, 2026 --

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial ACCESS Newswire 8:30 AM

-- February 17, 2026 --

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances ACCESS Newswire 8:30 AM

-- February 12, 2026 --

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets ACCESS Newswire 8:30 AM

-- February 10, 2026 --

IGC Pharma Announces Equity Research Update by Alliance Global Partners ACCESS Newswire 8:30 AM

-- February 9, 2026 --

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center ACCESS Newswire 8:30 AM

-- February 2, 2026 --

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation ACCESS Newswire 8:30 AM

-- January 22, 2026 --

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York ACCESS Newswire 9:00 AM

-- January 6, 2026 --

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability ACCESS Newswire 8:05 AM

-- January 5, 2026 --

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial ACCESS Newswire 9:00 AM

-- December 19, 2025 --

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum ACCESS Newswire 9:00 AM

-- December 15, 2025 --

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines ACCESS Newswire 9:00 AM

-- December 10, 2025 --

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75." ACCESS Newswire 9:00 AM

-- December 9, 2025 --

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial ACCESS Newswire 9:00 AM

-- December 2, 2025 --

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease ACCESS Newswire 9:00 AM

-- November 25, 2025 --

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends ACCESS Newswire 9:00 AM
Market Data Delayed 15 Minutes